Feil Family Brain and Mind Research Institute

The 11th annual Appel Alzheimer's Disease Research Institute Symposium brought together leading scientists and clinicians in the field to present the latest advances in understanding Alzheimer’s and related neurodegenerative diseases. 

Researchers at Weill Cornell Medicine, Cornell Tech and Cornell's Ithaca campus have demonstrated the use of AI-selected natural images and AI-generated synthetic images as neuroscientific tools for probing the visual processing areas of the brain.

Awards, honors and achievements for the month of July. 

People with dementia have protein build-up in astrocytes that may trigger abnormal antiviral activity and memory loss.

People with autism spectrum disorder can be classified into four distinct subtypes based on their brain activity and behavior.

A specific toxin-producing gut bacteria may be responsible for both triggering the onset of multiple sclerosis (MS) and ongoing disease activity.

Cigarette smoking is associated with worse cognitive performance among people 60 years and older, and that association is broadly the same whether or not individuals have hypertension or diabetes.

A gene linked to autism spectrum disorders plays a critical role in early brain development and may shape the formation of both normal and atypical nerve connections in the brain.

COVID-19 patients placed on ventilators can take a long time to regain consciousness. New research from Weill Cornell Medicine, NewYork-Presbyterian, MIT, and Massachusetts General Hospital is now illustrating that these delays may serve a purpose: protecting the brain from oxygen deprivation.

The 10th annual Appel Alzheimer's Disease Research Institute Symposium brought fascinating reports of progress in understanding Alzheimer’s and related neurodegenerative diseases.

Aggregates of the protein alpha-synuclein spread in the brains of people with Parkinson’s disease through a cellular waste-ejection process, suggests a new study led by Weill Cornell Medicine researchers.

The discovery of how to shift damaged brain cells from a diseased state into a healthy one poses a new potential path to treating Alzheimer’s and other forms of dementia.

The psychedelic drugs LSD and psilocybin activate serotonin receptors on brain cells in a way that reduces the energy needed for the brain to switch between different activity states, according to a study led by Weill Cornell Medicine researchers.

New study by The Rockefeller University and Weill Cornell Medicine investigators illuminates the distributed nature of memory processing in the brain, and provides new insights into the process of memory recall, which is less understood than memory storage.

Abnormalities in a type of brain cell called astrocytes may play a pivotal role in causing some behavioral symptoms of autism spectrum disorders, according to a preclinical study by Weill Cornell Medicine investigators.  

Inhibiting an important signaling pathway in brain-resident immune cells may calm brain inflammation and thereby slow the disease process in Alzheimer’s and some other neurodegenerative diseases, suggests a study by Weill Cornell Medicine investigators.

Most patients with severe COVID who are put on ventilators regain consciousness after removal of respiratory support, but recovery may take weeks after the period of mechanical ventilation has ended, according to a new study by investigators at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons, Harvard Medical School, .NewYork-Presbyterian and Massachusetts General Hospital.

A three-year contract from Wellcome Leap will allow a team of investigators from Weill Cornell Medicine, Stanford Medicine and UC San Diego School of Medicine to study new ways to combat depression and create models that can predict which treatment is likely to work for individual patients.

By mapping all the protein interactions of a dementia-linked protein in the brain called Tau, a team of Weill Cornell Medicine investigators has created a road map for identifying potential new treatment targets for Alzheimer’s disease and related dementia.

Multiple changes in brain cells during the first month of embryonic development may contribute to schizophrenia later in life.